Long-Term Safety and Efficacy of Delgocitinib Cream for Up to 52 Weeks in Adults with Chronic Hand Eczema: Results of the Phase 3 Open-Label Extension DELTA 3 Trial Following the DELTA 1 and 2 Trials
Phase 1 (Weeks 1 to 2): 0.25 mg subcutaneous injection once daily, morning on empty stomach Phase 2 (Weeks 3 to 6): Maintain 0.25 mg or increase to 0.5 mg based on response and tolerance Phase 3 (Weeks 7 to 8): Continue or begin taper depending on symptom improvement Maintenance: Consider cycling 4 weeks on, 2 weeks off for long-term management Oral dosing requires higher amounts to compensate for bioavailability differences
Cardiologists treating patients with atherosclerotic cardiovascular disease are increasingly initiating semaglutide as a cardiovascular risk modifier, adding an estimated 4.8 million new commercial GLP-1 patients annually
Some prefer injection day to be Sunday morning
Many cardiologists have recommended bariatric surgery but not usually the prescription medications due to concerns of cardiac and other toxicities, which should not be an issue with this medication. The data also show clinicians have a new opportunity to control obesity and its medical complications, including type 2 diabetes, according to Ken Fujioka, MD, former director of the Center for Weight Management and director of the Nutrition and Metabolic Research Center at Scripps Clinic San Diego